Clinical trials: AAA
Alzheimer Disease
Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD.
- Trial name
- NCT03443973
- Testing
- Gantenerumab
- Where
- 155 sites in United States, Argentina and 17 more
- Volunteers
- 975 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
Monetary Cost of Alzheimer's Disease in China
The purpose of the study is to estimate the Chinese economic burden in patients with Alzheimer's Disease (AD).
- Trial name
- NCT02694445
- Testing
- observation
- Where
- China
- Volunteers
- 3,098 people
- Sponsor
- Beijing Friendship Hospital
Alzheimer's Disease
Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil
To establish efficacy of Idalopirdine as adjunctive therapy to donepezil for symptomatic treatment of patients with mild-to-moderate Alzheimer's disease (AD).
- Trial name
- STARBEAM (NCT02006641)
- Testing
- Idalopirdine
- Where
- 162 sites in United States, Argentina and 17 more
- Volunteers
- 858 people
- Sponsor
- H. Lundbeck A/S
Abdominal Aortic Aneurysm
Preferences for Open Vs. Endovascular Repair for Abdominal Aortic Aneurysm
This study tests the use of a decision aid for Veterans who are facing a decision about surgery for their Abdominal Aortic Aneurysm (AAA).
- Trial name
- PROVE-AAA (NCT03115346)
- Testing
- Decision aid
- Where
- 22 sites in United States
- Volunteers
- 241 people
- Sponsor
- VA Office of Research and Development
Dementia, Mental Health
Compass for Care: A Theory-driven Mobile Solution to Promote Well-being Among Caregivers of Individuals With ADRD
In the US, the over 11 million Americans currently providing unpaid care to a family member, relative, or friend with Alzheimer's disease or a related dementia (ADRD) are over 6 times more likely than the general population to…
- Trial name
- Compass4Care (NCT06249139)
- Testing
- Compass for Care (Well-being intervention), Compass for Care (Safety intervention)
- Where
- United States
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- Pro-Change Behavior Systems
Alzheimer Disease
Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Alzheimer Disease
Impaired verbal communication is a cardinal symptom of Alzheimer Disease (AD) and the source of enormous distress and disability. Effective therapies for this deficit are lacking.
- Trial name
- NCT04482179
- Testing
- Active TMS, CILT
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Pennsylvania
Alzheimer's Disease
An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg intravenous (IV) every 4 weeks (Q4W) will be offered to all participants who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate…
- Trial name
- CREAD OLE (NCT03491150)
- Testing
- Crenezumab
- Where
- 66 sites in United States, Australia and 14 more
- Volunteers
- 149 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease, Psychotic Disorders
Antipsychotic Discontinuation in Alzheimer's Disease
In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established.
- Conditions
- Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
- Trial name
- ADAD (NCT00417482)
- Testing
- risperidone
- Where
- 7 sites in United States
- Volunteers
- 180 people
- Sponsor
- New York State Psychiatric Institute
Alzheimers Disease
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
The study is being conducted to understand how the medicine, semaglutide, affects the immune system and other biological processes in people with Alzheimer's disease.
- Trial name
- NCT05891496
- Testing
- Semaglutide
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 23 people
- Sponsor
- Novo Nordisk A/S
Alzheimer's Disease and Related Dementias, Quality of Life
Supporting Our Caregivers In ADRD Learning (SOCIAL)
Building on limitations of prior research, the investigators developed the Mindful and Self-Compassionate Care Program (MASC) to help caregivers of persons with Alzheimer Disease and Related Dementias (ADRD) manage stress…
- Conditions
- Alzheimer's Disease and Related Dementias, Quality of Life, Caregiver Stress
- Trial name
- SOCIAL (NCT06276023)
- Testing
- Mindful and Self-Compassionate Care Program (MASC), Health Education Program (HEP)
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Alzheimer Disease, Mild Cognitive Impairment
A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking
This is a longitudinal, observational study evaluating the imaging characteristics of the tau PET radioligand [18F]MK-6240 in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and Healthy Volunteer (HV) subjects.
- Trial name
- NCT03919669
- Testing
- All Subjects
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Thoracic Aortic Aneurysms, and Penetrating Atherosclerotic Ulcers
Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft
The purpose of this study is to evaluate the safety and efficacy of the Relay thoracic stent-graft system to treat thoracic aortic aneurysms.
- Trial name
- NCT00435942
- Testing
- Relay Thoracic Stent-Graft, Open Repair
- Where
- 27 sites in United States
- Volunteers
- 180 people
- Sponsor
- Bolton Medical
Alzheimers Disease
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
A study to evaluate the efficacy and safety of gantenerumab in amyloid-positive, cognitively unimpaired participants at risk for or at the earliest stages of AD.
- Trial name
- SKYLINE (NCT05256134)
- Testing
- Gantenerumab
- Where
- 63 sites in United States, Argentina and 8 more
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Abdominal Aortic Aneurysm (AAA)
ACZ885 for the Treatment of Abdominal Aortic Aneurysm
This study was designed to assess the safety, tolerability and efficacy of ACZ885 on aneurysmal growth rate in subjects with abdominal aortic aneurysms (AAA).
- Trial name
- AAA (NCT02007252)
- Testing
- ACZ885
- Where
- 9 sites in United States, Denmark and 3 more
- Volunteers
- 65 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease, Early Onset, Alzheimer Disease
A Safety Study of PTI-125 in Healthy Volunteers
A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Pharmacokinetic and Safety Study of PTl-125 in Healthy Volunteers
- Trial name
- NCT03784300
- Testing
- 50 mg PTI-125, 100 mg PTI-125, 200 mg PTI-125
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pain Therapeutics
Abdominal Aortic Aneurysms, Aorto-iliac Aneurysms
Zenith(R) Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Clinical Study
The Zenith(R) Fenestrated AAA Endovascular Graft Clinical Study is a clinical investigation approved by the US FDA to study the safety and effectiveness of the Zenith(R) Fenestrated AAA Endovascular Graft in the treatment of…
- Conditions
- Abdominal Aortic Aneurysms, Aorto-iliac Aneurysms, Juxtarenal Aneurysms
- Trial name
- NCT00875563
- Testing
- Zenith(R) Fenestrated AAA Endovascular Graft
- Where
- 14 sites in United States
- Volunteers
- 42 people
- Sponsor
- Cook Group Incorporated
Alzheimer's Disease, Agitation
Citalopram for Agitation in Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of citalopram for agitation in Alzheimer's dementia.
- Trial name
- CitAD (NCT00898807)
- Testing
- citalopram
- Where
- 8 sites in United States, Canada
- Volunteers
- 186 people
- Sponsor
- JHSPH Center for Clinical Trials
Alzheimer Disease
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational vaccine, plus QS-21 in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00960531
- Testing
- ACC-001+ QS21 (3mcg), ACC-001 (10 mcg) + QS-21, ACC-001+QS-21 (30mcg)
- Where
- 28 sites in United States
- Volunteers
- 160 people
- Sponsor
- Pfizer
Alzheimer's Disease
3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
This study will evaluate the effect of 150 mg MSDC-0160 taken daily for 90 days compared to the effect of placebo on changes in brain glucose utilization using FDG-PET and cognition in older persons with mild Alzheimer's disease.
- Trial name
- NCT01374438
- Testing
- MSDC-0160
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Metabolic Solutions Development Company
Alzheimer's Disease
A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease
This is a randomized double-blind placebo-controlled study comparing different doses of bryostatin for the treatment of moderately severe to severe Alzheimer's disease.
- Trial name
- NCT02431468
- Testing
- Bryostatin 1
- Where
- 29 sites in United States
- Volunteers
- 147 people
- Sponsor
- Neurotrope Bioscience, Inc.